Yousif Capital Management LLC Trims Position in Kenvue Inc. (NYSE:KVUE)

Yousif Capital Management LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 550,407 shares of the company’s stock after selling 29,000 shares during the quarter. Yousif Capital Management LLC’s holdings in Kenvue were worth $11,751,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Grove Bank & Trust lifted its position in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares in the last quarter. Riverview Trust Co purchased a new stake in shares of Kenvue during the third quarter worth about $30,000. Geneos Wealth Management Inc. bought a new stake in Kenvue during the 4th quarter valued at approximately $29,000. Ashton Thomas Securities LLC purchased a new position in Kenvue in the 3rd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC boosted its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Citigroup reduced their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $23.08.

Kenvue Price Performance

Shares of KVUE stock opened at $20.74 on Thursday. The company has a market capitalization of $39.76 billion, a P/E ratio of 37.70, a P/E/G ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company’s 50-day simple moving average is $21.77 and its two-hundred day simple moving average is $21.96.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 earnings per share. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.